Efficacy & Safety Study of Lorlatinib in ALK/ROS1 Metastatic NSCLC Patients With Compassionate Use Treatment
Clinical trial NCT05167500 · COMPLETED
Trial details
- NCT number
- NCT05167500
- Sponsor
- Fundación GECP
- Status
- COMPLETED
- Study type
- OBSERVATIONAL
- Start date
- 2021-12-09
- Primary completion
- 2022-12-30
- Enrollment
- 118
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.